

JAN - 6 1997

Raphael C. Giobbe, M.D.  
Radiation Safety Officer  
West Hudson Hospital  
206 Bergen Avenue  
Kearny, NJ 07032

Dear Dr. Giobbe:

In accordance with 10 CFR 35.14, your letter dated December 23, 1996 is accepted as notification that you have permitted Stewart A. Berkowitz, M.D. to work as an authorized user pursuant to 10 CFR 35.13(b)(1). No further correspondence on this matter is required.

Your license has been issued in the name of an institution, please ensure that all license notification, amendment or renewal requests are signed by a representative of the institution's management. This will assure that management has concurred with all commitments.

Your cooperation is appreciated.

Sincerely,

**ORIGINAL SIGNED BY:**  
**JO ANN V. STAMBAUGH**

JoAnn V. Stambaugh  
Division of Nuclear Materials Safety

License No. 29-08532-01  
Docket No. 030-02514  
Control No. 124071

Enclosure:  
10 CFR Part 35

DOCUMENT NAME: R:\WPS\MLTR\L2908532.01

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	N	DNMS/RI				
NAME	Stambaugh/jvs	gfs					
DATE	01/06/97	1/6/97	01/ /97		01/ /97		01/ /97

OFFICIAL RECORD COPY

**ML 10**

9703030442 970106  
PDR ADOCK 03002514  
C PDR





030-02514

West Hudson Radiology  
Department of Diagnostic Imaging  
206 Bergen Avenue  
Kearny, NJ 07032

Raphael C. Giobbe, M.D.  
Director  
Phone: (201) 955-7073  
Fax: (201) 955-1522

December 23, 1996

U.S. Nuclear Regulatory Commission  
Division of Nuclear Materials Safety  
Region I  
475 Allendale Road  
King-of-Prussia, Pennsylvania 19406-1415

Att: Michelle R. Beardsley

Re: License No. 29-08532-81

Dear Ms. Beardsley,


The purpose of this letter is to notify your that, as of the above date, the Radiation Safety Committee of West Hudson Hospital has approved and permitted Stewart A. Berkowitz, M.D., to work as an authorized user for materials and use as identified in 10CFR35.300 and 10CFR35.400, pursuant to 10CFR35.13(b)(3).

Dr. Berkowitz is currently identified as an authorized user for materials and use identified in 10CFR35.300 and 10CFR35.400 on Materials Licenses No.29-14017-01, No.29-01040-03, and No.29-18334-01 with copies of same enclosed.

Said notification is hereby give to comply with 10CFR35.14(a).

If you require any additional information, please feel free to contact me at (201)955-7073. Thank you

Sincerely,

  
Raphael C. Giobbe, M.D.  
Radiation Safety Officer.

m.g.

RCG/mas  
Enclosure

OFFICIAL RECORD COPY

ML 10

124071

JAN - 3 1997

# MATERIALS LICENSE

Amendment No. 15

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee  1. Wayne General Hospital  2. 224 Hamburg Turnpike Wayne, New Jersey 07470		In accordance with the application dated September 27, 1994, 3. License number 29-18334-01 is amended in its entirety to read as follows:	
		4. Expiration date February 29, 2000	
		5. Docket or Reference No 030-14870	
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed	
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200 except generators	B. As needed	
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed	
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy source identified in 10 CFR 35.400	D. 2000 millicuries	
E. Any byproduct material identified in 10 CFR 35.500	E. Any diagnostic source identified in 10 CFR 35.500	E. As needed	
9. Authorized use			
A. Any uptake, dilution and excretion procedure approved in 10 CFR 35.100.			
B. Any imaging and localization procedure approved in 10 CFR 35.200.			
C. Any radiopharmaceutical therapy procedure approved in 10 CFR 35.300.			
D. Any brachytherapy procedure approved in 10 CFR 35.400.			
E. Medical use of sealed sources included in 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).			

## CONDITIONS

10. Licensed material may be used only at the licensee's facilities at 224 Hamburg Turnpike, Wayne, New Jersey.
11. The Radiation Safety Officer for this license is Armand F. Leone, M.D.

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

29-18334-01

Docket or Reference Number

030-14870

Amendment No. 15

(Continued)

CONDITIONS

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized UsersMaterial and Use

Armand F. Leone, M.D.

35.100; 35.200; 35.300; 35.400  
In vitro studies

Rita Girolamo, M.D.

35.100; 35.200; 35.300  
In vitro studies

Rajmohan Hemu Shetty, M.D.

35.400

George Veliath, M.D.

35.100; 35.200; 35.300  
In vitro studies

Inwhan Whang, M.D.

35.100; 35.200; 35.300  
In vitro studies

Sam I. Brown, M.D.

35.300; 35.400

Sung IL Lee, M.D.

35.300; 35.400

Armand Leone, Jr., M.D.

35.100; 35.200; 35.300  
In vitro studies

Stewart A. Berkowitz, M.D.

35.300; 35.400

Jeffery Lindenbaum, M.D.

35.100; 35.200; 35.300

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d), 40.36(b), and 70.25(d) for establishing financial assurance for decommissioning.
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material at a single location to quantities below the limits specified in 10 CFR 30.72 which require consideration of the need for an emergency plan for responding to a release of licensed material.
15. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License Number

29-18334-01

Docket or Reference Number

030-14870

Amendment No. 15

(Continued)

CONDITIONS

16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated September 27, 1994  
B. Letter dated January 3, 1994

Date FEB - 5 1995

For the U.S. Nuclear Regulatory Commission

Original Signed By:

By Michelle Beardsley

Nuclear Materials Safety Branch  
Region I

King of Prussia, Pennsylvania 19406



NRC FORM 374  
(7-84)

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 3 PAGES

## MATERIALS LICENSE

Amendment No. 28

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

## Licensee

1. Kimball Medical Center  
2. 600 River Avenue  
Lakewood, New Jersey 08701

In accordance with the letter dated  
March 15, 1995,

3. License Number 29-14017-01 is amended in  
its entirety to read as follows:

4. Expiration Date November 30, 1998

5. Docket or  
Reference No. 030-01980

6. Byproduct, Source, and/or  
Special Nuclear Material7. Chemical and/or Physical  
Form8. Maximum Amount that Licensee  
May Possess at Any One Time  
Under This License

- A. Any byproduct material  
identified in 10 CFR  
35.100  
B. Any byproduct material  
identified in 10 CFR  
35.200  
C. Any byproduct material  
identified in 10 CFR  
35.300  
D. Iodine-125  
E. Any byproduct material  
identified in 10 CFR  
35.400

- A. Any radiopharmaceutical  
identified in 10 CFR  
35.100  
B. Any radiopharmaceutical  
identified in 10 CFR  
35.200 except gas  
C. Any radiopharmaceutical  
identified in 10 CFR  
35.300  
D. Sealed source (Amersham  
Model 1MC.P2 or AECL  
Model C-234)  
E. Any brachytherapy source  
identified in 10 CFR  
35.400

- A. As needed  
B. As needed  
C. 1000 millicuries  
D. 500 millicuries per  
source and 1,500  
millicuries total  
E. 2000 millicuries

## 9. Authorized use

- A. Any uptake, dilution and excretion procedure approved in 10 CFR 35.100.  
B. Any imaging and localization procedure approved in 10 CFR 35.200.  
C. Any radiopharmaceutical therapy procedure approved in 10 CFR 35.300 except thyroid carcinoma.  
D. Lixiscopes LSM-80-X (Series) or LSM-82-X (Series) for use approved in 10 CFR 35.500.  
E. Any brachytherapy procedure approved in 10 CFR 35.400.

## CONDITIONS

10. Licensed material may be used only at the licensee's facilities located at  
600 River Avenue, Lakewood, New Jersey.  
11. The Radiation Safety Officer for this license is Akhesh S. Desai, M.D.

NRC Form 374A  
(5-84)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

PAGE	2	OF	3	PAGES
License number	29-14017-01			
Document number	030-01980			
Amendment No. 28				

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Akhes S. Desai, M.D.	35.100; 35.200
Arthur Hirshkowitz, M.D.	35.100; 35.200
Bharat K. Patel, M.D.	35.100; 35.200
Chandru Uday Jain, M.D.	35.100; 35.200
Avinash C. Gupta, M.D.	35.200 for cardiovascular clinical procedures
Leslie Aufseeser, D.P.M.	Iodine 125 as identified in 35.500
Kevin T. McManus, M.D.	35.100; 35.200; 35.300
Vijay Sankhla, M.D.	35.100; 35.200
Stewart A. Berkowitz, M.D.	35.300; 35.400

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d), 40.36(b), and 70.25(d) for establishing financial assurance for decommissioning.
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material at a single location to quantities below the limits specified in 10 CFR 30.72 which require consideration of the need for an emergency plan for responding to a release of licensed material.
15. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

NRC Form 374A  
(2-84)

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 OF 3 PAGES

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number

29-14017-01


Docket or Reference number

030-01980

Amendment No. 28

16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application July 30, 1992  
except Attachment 10.14, Supplement B
- B. Letter dated March 25, 1993
- C. Letter dated October 5, 1993
- D. Letter dated November 3, 1994
- E. Letter dated November 30, 1994



For the U.S. Nuclear Regulatory Commission

Date JUL 26 1995

By

Nuclear Materials Safety Branch  
Region I

King of Prussia, Pennsylvania 19406



## MATERIALS LICENSE

Amendment No. 32

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

## Licensee

1. The General Hospital Center at Passaic

2. 350 Boulevard  
Passaic, New Jersey 07055In accordance with the letter dated  
July 12, 1994,3. License number 29-01040-03 is amended in  
its entirety to read as follows:

4. Expiration date February 28, 1999

5. Docket or  
Reference No 030-081306. Byproduct, source, and/or  
special nuclear material7. Chemical and/or physical  
form8. Maximum amount that licensee  
may possess at any one time  
under this licenseA. Any byproduct material  
identified in 10 CFR  
35.100B. Any byproduct material  
identified in 10 CFR  
35.200

C. Iodine 131

D. Strontium 89

E. Iodine 125

F. Palladium 103

A. Any radiopharmaceutical  
identified in 10 CFR  
35.100B. Any radiopharmaceutical  
identified in 10 CFR  
35.200, except gasC. Iodide as identified in  
10 CFR 35.300D. As identified in 10 CFR  
35.300E. Seeds identified in  
10 CFR 35.400F. Seeds identified in  
10 CFR 35.400

A. As needed

B. As needed

C. As needed

D. As needed

E. As needed

F. As needed

9. Authorized use

A. Any uptake, dilution and excretion procedure approved in 10 CFR 35.100.

B. Any imaging and localization procedure approved in 10 CFR 35.200.

C. Diagnosis and treatment of hyperthyroidism, and treatment of cardiac dysfunction.

D. Any radiopharmaceutical procedure approved in 10 CFR 35.300.

E. and F. Interstitial treatment of cancer.

## CONDITIONS

10. Licensed material may be used only at the licensee's facilities located at  
350 Boulevard, Passaic, New Jersey.

11. The Radiation Safety Officer for this license is Arthur Weisel, M.D.

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number

29-01040-03

Docket or Reference number

030-08130

Amendment No. 32

(Continued)

## CONDITIONS

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized UsersMaterial and Use

Milton Gallant, M.D.

35.100; 35.200; Iodine 131 for the treatment of hyperthyroidism and cardiac dysfunction

Mark L. Hebel, M.D.

35.100; 35.200; Iodine 131 for the treatment of hyperthyroidism and cardiac dysfunction

Arthur S. Weisel, M.D.

35.100; 35.200; Iodine 131 for the treatment of hyperthyroidism and cardiac dysfunction

Samuel I. Brown, M.D.

Strontium 89 for radiopharmaceutical procedures approved in 35.300; Iodine 125 and Paladium 103 seeds for interstitial treatment of cancer

Sung Il Lee, M.D.

Strontium 89 for radiopharmaceutical procedures approved in 35.300; Iodine 125 and Paladium 103 seeds for interstitial treatment of cancer

David R. Kozinn, M.D.

35.100; 35.200

Rajmohan Hemu Shetty, M.D.

Strontium 89 for radiopharmaceutical procedures approved in 35.300; Iodine 125 and Paladium 103 seeds for interstitial treatment of cancer

Stewart A. Berkowitz, M.D.

Strontium 89 for radiopharmaceutical procedures approved in 35.300; Iodine 125 and Paladium 103 seeds for interstitial treatment of cancer

Irwin Zarembok, M.D.

35.100; 35.200; Iodine 131 for the treatment of hyperthyroidism and cardiac dysfunction

Michael J. Edwards, M.D.

35.100; 35.200; Iodine 131 for the treatment of hyperthyroidism and cardiac dysfunction

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d), 40.36(b), and 70.25(d) for establishing financial assurance for decommissioning.

14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material at a single location to quantities below the limits specified in 10 CFR 30.72 which require consideration of the need for an emergency plan for responding to a release of licensed material.

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number

29-01040-03

Docket or Reference number

030-08130

Amendment No. 32

(Continued)

CONDITIONS

15. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application received August 26, 1993
- B. Letter dated January 3, 1994



For the U.S. Nuclear Regulatory Commission

Date AUG 25 1994

By

John V. Stambaugh

Nuclear Materials Safety Branch  
Region I

King of Prussia, Pennsylvania 19406

BETWEEN:

LICENSE FEE MANAGEMENT BRANCH, ARM  
AND  
REGIONAL LICENSING SECTIONS

(FOR LFMS USE)  
INFORMATION FROM LTS  
-----

PROGRAM CODE: 02120  
STATUS CODE: 0  
FEE CATEGORY: 7C  
EXP. DATE: 20030831  
FEE COMMENTS: CODE 23  
DECOM FIN ASSUR REQD: N  
.....

LICENSE FEE TRANSMITTAL

A. REGION *I*

1. APPLICATION ATTACHED  
APPLICANT/LICENSEE: WEST HUDSON HOSPITAL  
RECEIVED DATE: 970103  
DOCKET NO: 3002514  
CONTROL NO.: 124071  
LICENSE NO.: 29-08532-01  
ACTION TYPE: NOTIFICATIONS

2. FEE ATTACHED

AMOUNT: -----  
CHECK NO.: -----

3. COMMENTS

SIGNED  
DATE

*M. A. Perkins*  
-----  
11/6/97

B. LICENSE FEE MANAGEMENT BRANCH (CHECK WHEN MILESTONE 03 IS ENTERED /\_\_/) )

1. FEE CATEGORY AND AMOUNT: -----

2. CORRECT FEE PAID. APPLICATION MAY BE PROCESSED FOR:

AMENDMENT -----  
RENEWAL -----  
LICENSE -----

3. OTHER -----  
-----

SIGNED  
DATE

-----  
-----